Greenwich Net Cash Flow from Financing Trend from 2010 to 2022

GLSI -  USA Stock  

USD 8.48  0.07  0.83%

Greenwich Lifesciences Net Cash Flow from Financing is increasing over the last several years with slightly volatile swings. Net Cash Flow from Financing is estimated to finish at about 2.9 M this year. During the period from 2010 to 2022 Greenwich Lifesciences Net Cash Flow from Financing regressed destribution of quarterly values had coefficient of variationof 281.98 and r-squared of  0.15. The current Consolidated Income is estimated to decrease to about (4.9 M). The current Earning Before Interest and Taxes EBIT is estimated to decrease to about (4.9 M).
  
Refresh
Check Greenwich Lifesciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Greenwich main balance sheet or income statement drivers, such as Operating Expenses of 4.1 M, Research and Development Expense of 3.1 M or Selling General and Administrative Expense of 992.8 K, as well as many exotic indicators such as Book Value per Share of 2.24, Current Ratio of 76.24 or Debt to Equity Ratio of 0.0151. Greenwich financial statements analysis is a perfect complement when working with Greenwich Lifesciences Valuation or Volatility modules. It can also supplement various Greenwich Lifesciences Technical models. Please check the analysis of Greenwich Lifesciences Correlation against competitors.

Greenwich Lifesciences Quarterly Net Cash Flow from Financing

(5.51 Million)

Share

Greenwich Net Cash Flow from Financing Breakdown

Showing smoothed Net Cash Flow from Financing of Greenwich Lifesciences with missing and latest data points interpolated. A component of Net Cash Flow or Change in Cash and Cash Equivalents representing the amount of cash inflow (outflow) from financing activities; from continuing and discontinued operations. Principal components of financing cash flow are: issuance (purchase) of equity shares; issuance (repayment) of debt securities; and payment of dividends & other cash distributions.Greenwich Lifesciences' Net Cash Flow from Financing historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Greenwich Lifesciences' overall financial position and show how it may be relating to other accounts over time.
Net Cash Flow from Financing10 Years Trend
Increasing
Slightly volatile
 Net Cash Flow from Financing 
Share
      Timeline 

Greenwich Net Cash Flow from Financing Regression Statistics

Arithmetic Mean 2,889,769
Geometric Mean 445,304
Coefficient Of Variation 281.98
Mean Deviation 4,144,157
Median 200,000
Standard Deviation 8,148,527
Range 29,606,502
R-Value 0.39
R-Squared 0.15
Significance 0.19
Slope 812,684

Greenwich Net Cash Flow from Financing History

2019215 K
202029.8 M
20212.8 M
20222.9 M

About Greenwich Lifesciences Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Greenwich Lifesciences income statement, its balance sheet, and the statement of cash flows. Greenwich Lifesciences investors use historical funamental indicators, such as Greenwich Lifesciences's Net Cash Flow from Financing, to determine how well the company is positioned to perform in the future. Although Greenwich Lifesciences investors may use each financial statement separately, they are all related. The changes in Greenwich Lifesciences's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Greenwich Lifesciences's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Greenwich Lifesciences Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Greenwich Lifesciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Net Cash Flow from Financing2.8 M2.9 M
Free Cash Flow-4.3 M-4.4 M
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2neu-expressing cancers. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas. Greenwich Lifesciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3 people.

Greenwich Lifesciences Investors Sentiment

The influence of Greenwich Lifesciences' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Greenwich. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Greenwich Lifesciences in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Greenwich Lifesciences' short interest history, or implied volatility extrapolated from Greenwich Lifesciences options trading.

Current Sentiment - GLSI

Greenwich Lifesciences Investor Sentiment

Macroaxis portfolio users are indifferent in their judgment towards investing in Greenwich Lifesciences. What is your judgment towards investing in Greenwich Lifesciences? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Greenwich Lifesciences using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please check the analysis of Greenwich Lifesciences Correlation against competitors. Note that the Greenwich Lifesciences information on this page should be used as a complementary analysis to other Greenwich Lifesciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.

Complementary Tools for Greenwich Stock analysis

When running Greenwich Lifesciences price analysis, check to measure Greenwich Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Greenwich Lifesciences is operating at the current time. Most of Greenwich Lifesciences' value examination focuses on studying past and present price action to predict the probability of Greenwich Lifesciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Greenwich Lifesciences' price. Additionally, you may evaluate how the addition of Greenwich Lifesciences to your portfolios can decrease your overall portfolio volatility.
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Is Greenwich Lifesciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Greenwich Lifesciences. If investors know Greenwich will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Greenwich Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Greenwich Lifesciences is measured differently than its book value, which is the value of Greenwich that is recorded on the company's balance sheet. Investors also form their own opinion of Greenwich Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Greenwich Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Greenwich Lifesciences' market value can be influenced by many factors that don't directly affect Greenwich Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Greenwich Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Greenwich Lifesciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Greenwich Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.